Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.
Feasibility of future HIV vaccine trials in New York City injecting drug users (IDUs) and their sexual partners.
Int Conf AIDS. 1993 Jun 6-11;9(1):101 (abstract no. WS-C20-4). Unique Identifier : AIDSLINE MED/93333228 Mannor M; Wolfe H; Des Jarlais D; Krasinski K; Maslansky R; Simberkoff M; New York Univ. School of Med., NY.
Abstract:
OBJECTIVES: (1) To recruit and follow at 3-monthly intervals 500 high-risk HIV-negative (HIV-) subjects who, in the previous 6 months, reported injected drug use or sex with an IDU; (2) to assess seroconversion, and (3) to assess factors affecting recruitment, retention, and interest in participating in preventive vaccine trials. METHODS: Between 7/1/92 and 11/15/92, 512 eligible subjects were identified through 3 sources. 1: HIV- or -unknown methadone maintenance patients. 2: Subjects identified as HIV- in a previous study. 3: Respondents to flyers distributed by cohort subjects to social contacts or by health care personnel to clinic patients. Source 3 subjects were prescreened over a toll-free telephone line for eligibility. A volunteer fee of $15 was given to subjects at intake; eligible subjects were told this amount would increase by $5 per visit at subsequent visits. RESULTS: 53% (301/564) of Source 1 and 71% 58/82) of Source 2 subjects were eligible for cohort entry. 94% of Source 3 subjects indicated in the telephone pre-screen that they were eligible, 84% of those scheduled for interview arrived, and 66% (153/231) of those interviewed were eligible. Cohort description: 26% female, 37% Latino, 32% Afro-American, 28% Caucasian. Mean age = 39 years (range = 18-66). In the 6 months prior to intake, 65% injected drugs, 28% shared needles, and 66% had sex with an IDU. 15% (76) shared needles or had sex with an HIV+ person. Source 3 subjects were significantly more likely to have shared needles, and to have had an HIV+ sex or needle-sharing partner 70% of subjects contacted for first recall had been interviewed as of 1/15/93: 85% were "very" or "somewhat" vs "not at all") interested in participating in future vaccine trials. CONCLUSIONS: High HIV seroprevalence in NYC IDUs makes assembly of a cohort of high-risk HIV- difficult. We found flyers and a toll-free telephone line to be important tools in the enlistment of high-risk subjects. Early results indicated adequate retention of subjects recruited in this manner.
Keywords: *Acquired Immunodeficiency Syndrome/PREVENTION & CONTROL *AIDS Vaccines/THERAPEUTIC USE *HIV *Sex Behavior *Substance Abuse, Intravenous 931130
M93B5819
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.
